Slide 1: Second Quarter 2023 Earnings
Second Quarter 2023 Earnings A u g u s t 8 , 2 0 2 3
Slide 2: Forward-looking statements
These presentations contain forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words “may,” “will,” “expect,” “believe,” “anticipate,” “plan,” “estimate,” “project,
Slide 3: Second Quarter 2023 Financial Highlights
Consolidated Revenue $455 million Second Quarter 2023 Financial Highlights(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masimo.com to access additional informa
Slide 4: Second Quarter 2023 Results | Non-GAAP
(In millions; except EPS) Actual Prior Year Revenue $455 $565 -19% Healthcare 281 357 -21% Non-Healthcare 174 208 -16% Gross Profit $228 $309 -26% Healthcare 169 237 -29% Non-Healthcare 59 73 -19% Gross Margin 50.0% 54.7% -470 bps Healthcare 60.1% 66.3% -620 bps Non-Healthcare 33.6% 34.8% -120 bps O
Slide 5: Full Year 2023 Guidance as of August 8, 2023
Consolidated Revenue $2,100 to $2,200 million Full Year 2023 Guidance as of August 8, 2023(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masimo.com to access ad
Slide 6: Full Year 2023 Guidance | Non-GAAP
Guidance vs. Prior Year (In millions; except EPS) Low High Prior Year Low High Revenue $2,100 $2,200 $2,036 3% 8% Healthcare 1,300 1,350 1,340 -3% 1% Non-Healthcare 800 850 695 15% 22% Gross Profit $1,079 $1,138 $1,123 -4% 1% Healthcare 800 836 870 -8% -4% Non-Healthcare 278 302 252 10% 20% Gross Ma
Slide 7: 2023 Guidance Summary as of August 8, 2023
2023 Guidance Summary as of August 8, 2023(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masimo.com to access additional information related to our Non-GAAP adj
Slide 8: Healthcare Contracting
Through the second quarter of each year Healthcare Contracting | Through Second Quarter Worldwide Healthcare Incremental Value of New Contracts(1) Worldwide Healthcare Unrecognized Contract Revenue(2) As of the end of the second quarter of each year U.S. Healthcare Incremental Value of New Contracts
Slide 9: Appendices: GAAP to Non-GAAP Reconciliations
Appendices GAAP to Non-GAAP Reconciliations
Slide 10: Consolidated Income Statement
Consolidated Income Statement (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on August 8, 2023. (Unaudited; in millions, except per share data) (1) Quarter to Date Full Year Q3 2023 Gu
Slide 11: Consolidated Income Statement
Consolidated Income Statement (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on August 8, 2023. (Unaudited; in millions, except per share data) (1) Quarter to Date Full Year Q3 2023 Gu
Slide 12: Revenue
Revenue (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on August 8, 2023. (3) Constant currency adjustments are intended to reflect revenue at prior year foreign exchange rates for com
Slide 13: Segment Reporting
Segment Reporting (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on August 8, 2023. (Unaudited; in millions) (1) Quarter to Date Full Year Q3 2023 Guidance (2) FY 2023 Guidance (2) Q1